Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

Concerns about the reliability of KX-826's phase 3 results from China due to potential fraud in clinical trials. Discussion includes skepticism about trusting these results.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for alopecia treatment. They enhance cell viability, maintain stemness, and induce hair growth without teratoma formation.

A new sugar gel for hair regrowth shows promise, but its effectiveness and safety are uncertain, especially since it was tested on mice and may have risks like tumor development. Ingredients for the gel include sodium alginate, propylene glycol, 2-phenoxyethanol, and 2-deoxy-D-ribose sugar.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

Pyrilutamide failed phase 2 efficiency, leading to discussions about Kintor's investment in GT20029 and the potential benefits of having multiple products. Users debated the effectiveness of different treatments, including pyrilutamide and GT20029, and the strategic reasons for developing both.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A user plans to create a copper peptide hair serum with GHK-Cu and AHK-Cu, considering adding 5% minoxidil but avoiding finasteride and dutasteride. They seek suggestions for improving the product without complicating it.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.